Published by Chapman and Hall/CRC 2016-06-16, 2016
ISBN 10: 1498709559 ISBN 13: 9781498709552
Seller: Chiron Media, Wallingford, United Kingdom
Hardcover. Condition: New.
Published by Routledge, 2016
ISBN 10: 1498709559 ISBN 13: 9781498709552
Seller: Biblios, Frankfurt am main, HESSE, Germany
Condition: New.
Published by Routledge, 2016
ISBN 10: 1498709559 ISBN 13: 9781498709552
Seller: Lucky's Textbooks, Dallas, TX, U.S.A.
Condition: New.
Published by Taylor & Francis Inc, 2016
ISBN 10: 1498709559 ISBN 13: 9781498709552
Seller: THE SAINT BOOKSTORE, Southport, United Kingdom
Hardback. Condition: New. New copy - Usually dispatched within 4 working days.
Published by CRC Press, 2016
ISBN 10: 1498709559 ISBN 13: 9781498709552
Seller: PBShop.store US, Wood Dale, IL, U.S.A.
HRD. Condition: New. New Book. Shipped from UK. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000.
Published by CRC Press Jun 2016, 2016
ISBN 10: 1498709559 ISBN 13: 9781498709552
Seller: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Germany
Buch. Condition: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Reliably optimizing a new treatment in humans is a critical first step in clinical evaluation since choosing a suboptimal dose or schedule may lead to failure in later trials. At the same time, if promising preclinical results do not translate into a real treatment advance, it is important to determine this quickly and terminate the clinical evaluation process to avoid wasting resources. Bayesian Designs for Phase I-II Clinical Trials describes how phase I-II designs can serve as a bridge or protective barrier between preclinical studies and large confirmatory clinical trials. It illustrates many of the severe drawbacks with conventional methods used for early-phase clinical trials and presents numerous Bayesian designs for human clinical trials of new experimental treatment regimes.Written by research leaders from the University of Texas MD Anderson Cancer Center, this book shows how Bayesian designs for early-phase clinical trials can explore, refine, and optimize new experimental treatments. It emphasizes the importance of basing decisions on both efficacy and toxicity. 324 pp. Englisch.
Published by Chapman and Hall/CRC, 2016
ISBN 10: 1498709559 ISBN 13: 9781498709552
Seller: Ria Christie Collections, Uxbridge, United Kingdom
Condition: New. PRINT ON DEMAND Book; New; Fast Shipping from the UK. No. book.
Published by CRC Press, 2016
ISBN 10: 1498709559 ISBN 13: 9781498709552
Seller: PBShop.store UK, Fairford, GLOS, United Kingdom
HRD. Condition: New. New Book. Delivered from our UK warehouse in 4 to 14 business days. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000.
Published by Chapman & Hall, 2016
ISBN 10: 1498709559 ISBN 13: 9781498709552
Seller: Revaluation Books, Exeter, United Kingdom
Hardcover. Condition: Brand New. 1st edition. 310 pages. 9.25x6.25x0.75 inches. In Stock.
Published by CRC Press, 2016
ISBN 10: 1498709559 ISBN 13: 9781498709552
Seller: moluna, Greven, Germany
Gebunden. Condition: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. Ying Yuan is a professor and co-chief of the Section of Adaptive Clinical Trials in the Department of Biostatistics at the University of Texas MD Anderson Cancer Center. He is also an adjunct associate professor in the Department of Stat.
Published by Chapman & Hall, 2016
ISBN 10: 1498709559 ISBN 13: 9781498709552
Seller: Revaluation Books, Exeter, United Kingdom
Hardcover. Condition: Brand New. 1st edition. 310 pages. 9.25x6.25x0.75 inches. In Stock.
Published by CRC Press, 2016
ISBN 10: 1498709559 ISBN 13: 9781498709552
Seller: AHA-BUCH GmbH, Einbeck, Germany
Buch. Condition: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - Reliably optimizing a new treatment in humans is a critical first step in clinical evaluation since choosing a suboptimal dose or schedule may lead to failure in later trials. At the same time, if promising preclinical results do not translate into a real treatment advance, it is important to determine this quickly and terminate the clinical evaluation process to avoid wasting resources. Bayesian Designs for Phase I-II Clinical Trials describes how phase I-II designs can serve as a bridge or protective barrier between preclinical studies and large confirmatory clinical trials. It illustrates many of the severe drawbacks with conventional methods used for early-phase clinical trials and presents numerous Bayesian designs for human clinical trials of new experimental treatment regimes.Written by research leaders from the University of Texas MD Anderson Cancer Center, this book shows how Bayesian designs for early-phase clinical trials can explore, refine, and optimize new experimental treatments. It emphasizes the importance of basing decisions on both efficacy and toxicity.
Published by Taylor & Francis Inc, 2016
ISBN 10: 1498709559 ISBN 13: 9781498709552
Seller: THE SAINT BOOKSTORE, Southport, United Kingdom
Hardback. Condition: New. This item is printed on demand. New copy - Usually dispatched within 5-9 working days.
Published by Chapman and Hall/CRC, 2016
ISBN 10: 1498709559 ISBN 13: 9781498709552
Seller: Mispah books, Redhill, SURRE, United Kingdom
Hardcover. Condition: Like New. Like New. book.